<?xml version="1.0" encoding="UTF-8"?>
<paload id="" version="">
	<toplevel>
		<routedMedId>156713</routedMedId>
		<routedMedName>Orencia subcutaneous</routedMedName>
		<routedGenericName>abatacept subcutaneous</routedGenericName>
		<etcIds>
			<?oxy_comment_start author="paulnguyen" timestamp="20141211T161523-0800" comment="C: ETC 5913 is DMARD - Antinflammatory, Select. costimuation modulator, T-cell inhib.  ETC 3965 is the more general (i.e. Disease Modifying Anti-Rheumatoid Drugs (DMARD))."?>
			<etc_id><?oxy_comment_end?>3965</etc_id>
		</etcIds>
		<medIds>
			<medId>565613</medId>
			<medId>476036</medId>
		</medIds>
	</toplevel>
	<diagnoses>
		<diagnosis>
			<?oxy_comment_start author="paulnguyen" timestamp="20141211T164116-0800" comment="C: When assessments are ready, need to add TB and criteria for evaluating RA."?>
			<fqn><?oxy_comment_end?>Rheumatoid Arthritis-moderate to severe</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.2805</icd9>
			<symbolic>Orencia-RA</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name>moderate to severe</name>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Rheumatology</name>
					<code>207RR0500X</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name>Severe Infection</name>
					<code>22.413</code>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>exclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>allorder</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.20909|02.16551|02.6260</codeValues>
								<selectedListName>Disease Modifying Anti-Rheumatoid Drugs (DMARD)</selectedListName>
								<selectedListClassCode>09.3965</selectedListClassCode>
								<durModifier>ge</durModifier>
								<dur>3</dur>
								<durUnit>m</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.150396|02.16772|02.64713|02.16554|02.152287</codeValues>
								<selectedListName>Tumor Necrosis Factor (TNF) Inhibitors</selectedListName>
								<selectedListClassCode>16.13</selectedListClassCode>
								<durModifier>ge</durModifier>
								<dur>3</dur>
								<durUnit>m</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.164880|02.164878|02.164879|02.15402|02.94519|02.154546|02.166545|02.150450|02.94107|02.150652|02.95020|02.9755|02.11314|02.150614|02.144377</codeValues>
								<selectedListName>Live Vaccines</selectedListName>
								<selectedListClassCode>09.6421</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.150396|02.154223|02.154650|02.16772|02.144657|02.64713|02.144769|02.167140|02.147784|02.152021|02.16554|02.152287|02.164798</codeValues>
								<selectedListName>Tumor Necrosis Factor (TNF) Inhibitors</selectedListName>
								<selectedListClassCode>16.13</selectedListClassCode>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.165329|02.22175|02.156713|02.94819|02.165957|02.165956|02.5206|02.162865</codeValues>
								<selectedListName>Non-TNF Biologic DMARD</selectedListName>
								<selectedListClassCode>16.16</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.152794</codeValues>
								<selectedListName>Anti-inflammatory - Interleukin-1 beta Blockers</selectedListName>
								<selectedListClassCode>09.6212</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.153035</codeValues>
								<selectedListName>Antipsoriatic Agents - MC Antibody, Human Interleukin 12/23 Inhibitors</selectedListName>
								<selectedListClassCode>09.6200</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text>SubQ: 125 mg once weekly, with or without an initial IV loading dose.</text>
				<text>Weight &lt;60 kg: 500 mg IV at weeks 0, 2, and 4.  Then 500 mg every 4 weeks thereafter.</text>
				<text>Weight 60 to 100 kg: 750 mg IV at weeks 0, 2, and 4.  Then 750 mg every 4 weeks thereafter.</text>
				<text>Weight > 100 kg: 1000 mg IV at weeks 0, 2, and 4.  Then 1000 mg every 4 weeks thereafter.</text>
			</dosing>
			<instructions>
				<instruction>For members initiating therapy with an IV loading dose, administer a single IV dose based upon their body weight, followed by a single subcutaneous injection within 1 day.</instruction>
				<instruction>For members transitioning from IV to subcutaneous injection, administer the first subcutaneous dose instead of the next scheduled IV dose.</instruction>
			</instructions>
			<qlimits>
				<qlimit>
					<medId>565613</medId>
					<initPerDayDesc>Not specified</initPerDayDesc>
					<initPerIntervalDesc>4 syringes every 4 weeks</initPerIntervalDesc>
					<renewPerDayDesc>Not specified</renewPerDayDesc>
					<renewPerIntervalDesc>4 syringes every 4 weeks</renewPerIntervalDesc>
				</qlimit>
				<qlimit>
					<medId>476036</medId>
					<initPerDayDesc>Not specified</initPerDayDesc>
					<initPerIntervalDesc>Up to 12 vials for the first 4 weeks, then up to 4 vials every 4 weeks thereafter.</initPerIntervalDesc>
					<renewPerDayDesc>Not specified</renewPerDayDesc>
					<renewPerIntervalDesc>Up to 4 vials every 4 weeks.</renewPerIntervalDesc>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur>1</dur>
					<durUnit>y</durUnit>
				</initialDur>
				<renewalDur>
					<dur>1</dur>
					<durUnit>y</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Orencia [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2013</reference>
				<reference>Singh JA, Furst DE, Bharat A, et al.  2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis.  Arthritis Care &amp; Research. 2012; 64: 625-39. DOI 10.1002/acr.21641</reference>
				<reference>Saag KG, Teng GG, Patkar NM, et al.  American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis.  Arthritis Care &amp; Research.  2008; 59: 762-84.  DOI 10.1002/art.23721</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives/>
		</diagnosis>
		<diagnosis>
			<?oxy_comment_start author="paulnguyen" timestamp="20141212T155814-0800" comment="C: Need to add criteria for determining severity when assessments are done."?>
			<fqn><?oxy_comment_end?>Juvenile Idiopathic Arthritis-moderate to severe</fqn>
			<age>
				<ageRangeType>range</ageRangeType>
				<ageRangeMin>6</ageRangeMin>
				<ageRangeMax>17</ageRangeMax>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.14082</icd9>
			<symbolic>Orencia-JIA</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name>moderate to severe</name>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Pediatric Rheumatology</name>
					<code>2080P0216X</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name>Severe Infection</name>
					<code>22.413</code>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>exclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<?oxy_comment_start author="paulnguyen" timestamp="20141212T145524-0800" comment="C: Per guidelines, NSAIDs should not be used for more than 2 months and repeated intra-articular glucocorticoid injections have uncertain benefits."?>
						<numRequired><?oxy_comment_end?>allorder</numRequired>
						<treatment>
							<treatmentLine>
								<option>AND</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.20909|02.16551|02.22470</codeValues>
								<selectedListName>Disease Modifying Anti-Rheumatoid Drugs (DMARD)</selectedListName>
								<selectedListClassCode>09.3965</selectedListClassCode>
								<durModifier>ge</durModifier>
								<dur>3</dur>
								<durUnit>m</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>AND</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.16772|02.64713|02.16554</codeValues>
								<selectedListName>Tumor Necrosis Factor (TNF) Inhibitors</selectedListName>
								<selectedListClassCode>16.13</selectedListClassCode>
								<durModifier>ge</durModifier>
								<dur>3</dur>
								<durUnit>m</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.164880|02.164878|02.164879|02.15402|02.94519|02.154546|02.166545|02.150450|02.94107|02.150652|02.95020|02.9755|02.11314|02.150614|02.144377</codeValues>
								<selectedListName>Live Vaccines</selectedListName>
								<selectedListClassCode>09.6421</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.150396|02.154223|02.154650|02.16772|02.144657|02.64713|02.144769|02.167140|02.147784|02.152021|02.16554|02.152287|02.164798</codeValues>
								<selectedListName>Tumor Necrosis Factor (TNF) Inhibitors</selectedListName>
								<selectedListClassCode>16.13</selectedListClassCode>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.165329|02.22175|02.156713|02.94819|02.165957|02.165956|02.5206|02.162865</codeValues>
								<selectedListName>Non-TNF Biologic DMARD</selectedListName>
								<selectedListClassCode>16.16</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.152794</codeValues>
								<selectedListName>Anti-inflammatory - Interleukin-1 beta Blockers</selectedListName>
								<selectedListClassCode>09.6212</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.153035</codeValues>
								<selectedListName>Antipsoriatic Agents - MC Antibody, Human Interleukin 12/23 Inhibitors</selectedListName>
								<selectedListClassCode>09.6200</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text>Weight &lt;75 kg: 10 mg/kg (based on members weight at time of administration) IV at weeks 0, 2, and 4.  Then every 4 weeks thereafter.</text>
				<text>Weight 75 to 100 kg: 750 mg IV at weeks 0, 2, and 4.  Then 750 mg every 4 weeks thereafter.</text>
				<text>Weight >100 kg: 1000 mg IV at weeks 0, 2, and 4.  Then 1000 mg every 4 weeks thereafter.</text>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId>476036</medId>
					<initPerDayDesc>Not specified</initPerDayDesc>
					<initPerIntervalDesc>Up to 12 vials for the first 4 weeks, then up to 4 vials every 4 weeks thereafter.</initPerIntervalDesc>
					<renewPerDayDesc>Not specified</renewPerDayDesc>
					<renewPerIntervalDesc>Up to 4 vials every 4 weeks.</renewPerIntervalDesc>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur>1</dur>
					<durUnit>y</durUnit>
				</initialDur>
				<renewalDur>
					<dur>1</dur>
					<durUnit>y</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Orencia [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2013</reference>
				<reference>Ringold S, Weiss PF, Beukelman T, et al.  2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis.  Arthritis &amp; Rheumatism.  2013; 65: 2499-2512.  DOI 10.1002/art.38092</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives/>
		</diagnosis>
	</diagnoses>
	<precautions>
		<geriatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</geriatric>
		<pregnancy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pregnancy>
		<pediatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pediatric>
		<lactation>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</lactation>
		<allergy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</allergy>
		<sideEffect>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</sideEffect>
		<drugDisease>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</drugDisease>
	</precautions>
	<lists>
		<listDef>
			<name>Disease Modifying Anti-Rheumatoid Drugs (DMARD)</name>
			<codeValue>09.3965</codeValue>
			<?oxy_comment_start author="paulnguyen" timestamp="20141212T104214-0800" comment="C: The text form says &apos;class&apos;.  The error goes away when it is changed to &apos;drugclass&apos;.  See if &apos;class&apos; causes and upload error and if it does, then is it fixed when changed to &apos;drugclass&apos;.

Also get an error when selecting &apos;Generic Drug&apos;"?>
			<listType><?oxy_comment_end?>drugclass</listType>
			<listItem>
				<name>methotrexate sodium oral</name>
				<codeValue>02.20909</codeValue>
			</listItem>
			<listItem>
				<name>leflunomide oral</name>
				<codeValue>02.16551</codeValue>
			</listItem>
			<listItem>
				<name>sulfasalazine oral</name>
				<codeValue>02.6260</codeValue>
			</listItem>
			<listItem>
				<name>sulfsalazine EC oral</name>
				<codeValue>02.22470</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>Tumor Necrosis Factor (TNF) Inhibitors</name>
			<codeValue>16.13</codeValue>
			<listType>adhoc</listType>
			<listItem>
				<name>Cimzia subcutaneous</name>
				<codeValue>02.150396</codeValue>
			</listItem>
			<listItem>
				<name>Cimzia Starter Kit subcutaneous</name>
				<codeValue>02.154223</codeValue>
			</listItem>
			<listItem>
				<name>Cimzia Powder for Reconstitution subcutaneous</name>
				<codeValue>02.154650</codeValue>
			</listItem>
			<listItem>
				<name>Enbrel subcutaneous</name>
				<codeValue>02.16772</codeValue>
			</listItem>
			<listItem>
				<name>Enbrel SureClick subcutaneous</name>
				<codeValue>02.144657</codeValue>
			</listItem>
			<listItem>
				<name>Humira subcutaneous</name>
				<codeValue>02.64713</codeValue>
			</listItem>
			<listItem>
				<name>Humira Pen subcutaneous</name>
				<codeValue>02.144769</codeValue>
			</listItem>
			<listItem>
				<name>Humira Ped Crohn's Starter Pack subcutaneous</name>
				<codeValue>02.167140</codeValue>
			</listItem>
			<listItem>
				<name>Humira Crohn's Disease Starter Pack subcutaneous</name>
				<codeValue>02.147784</codeValue>
			</listItem>
			<listItem>
				<name>Humira Psoriasis Starter Pack subcutaneous</name>
				<codeValue>02.152021</codeValue>
			</listItem>
			<listItem>
				<name>Remicade intravenous</name>
				<codeValue>02.16554</codeValue>
			</listItem>
			<listItem>
				<name>Simponi subcutaneous</name>
				<codeValue>02.152287</codeValue>
			</listItem>
			<listItem>
				<name>Simponi ARIA intravenous</name>
				<codeValue>02.164798</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>Non-TNF Biologic DMARD</name>
			<codeValue>16.16</codeValue>
			<listType>adhoc</listType>
			<listItem>
				<name>Actemra subcutaneous</name>
				<codeValue>02.165329</codeValue>
			</listItem>
			<listItem>
				<name>Actemra intravenous</name>
				<codeValue>02.153521</codeValue>
			</listItem>
			<listItem>
				<name>Kineret subcutaneous</name>
				<codeValue>02.22175</codeValue>
			</listItem>
			<listItem>
				<name>Otezla Starter oral</name>
				<codeValue>02.165957</codeValue>
			</listItem>
			<listItem>
				<name>Otezla oral</name>
				<codeValue>02.165956</codeValue>
			</listItem>
			<listItem>
				<name>Rituxan intravenous</name>
				<codeValue>02.5206</codeValue>
			</listItem>
			<listItem>
				<name>Xeljanz oral</name>
				<codeValue>02.162865</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>Live Vaccines</name>
			<codeValue>09.6421</codeValue>
			<listType>adhoc</listType>
			<listItem>
				<name>adenovirus vaccine live type-4 and 7 oral</name>
				<codeValue>02.164880</codeValue>
			</listItem>
			<listItem>
				<name>adenovirus vaccine live type-4 oral</name>
				<codeValue>02.164878</codeValue>
			</listItem>
			<listItem>
				<name>adenovirus vaccine live type-7 oral</name>
				<codeValue>02.164879</codeValue>
			</listItem>
			<listItem>
				<name>Theracys intravesical</name>
				<codeValue>02.15402</codeValue>
			</listItem>
			<listItem>
				<name>Tice BCG intravesical</name>
				<codeValue>02.94519</codeValue>
			</listItem>
			<listItem>
				<name>BCG vaccine, live (PF) percutaneous</name>
				<codeValue>02.154546</codeValue>
			</listItem>
			<listItem>
				<name>Flumist Quad 2014-2015 nasal</name>
				<codeValue>02.166545</codeValue>
			</listItem>
			<listItem>
				<name>M-M-R II (PF) subcutaneous</name>
				<codeValue>02.150450</codeValue>
			</listItem>
			<listItem>
				<name>ProQuad (PF) subcutaneous</name>
				<codeValue>02.94107</codeValue>
			</listItem>
			<listItem>
				<name>Rotarix oral</name>
				<codeValue>02.150652</codeValue>
			</listItem>
			<listItem>
				<name>RotaTeq Vaccine oral</name>
				<codeValue>02.95020</codeValue>
			</listItem>
			<listItem>
				<name>Vivotif Berna Vaccine oral</name>
				<codeValue>02.9755</codeValue>
			</listItem>
			<listItem>
				<name>Varivax (PF) subcutaneous</name>
				<codeValue>02.11314</codeValue>
			</listItem>
			<listItem>
				<name>YF-Vax (PF) subcutaneous</name>
				<codeValue>02.150614</codeValue>
			</listItem>
			<listItem>
				<name>ZOSTAVAX  subcutaneous</name>
				<codeValue>02.144377</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>Anti-inflammatory - Interleukin-1 beta Blockers</name>
			<codeValue>09.6212</codeValue>
			<listType>drugclass</listType>
			<listItem>
				<name>Ilaris (PF) subcutaneous</name>
				<codeValue>02.152794</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>Antipsoriatic Agents - MC Antibody, Human Interleukin 12/23 Inhibitors</name>
			<codeValue>09.6200</codeValue>
			<listType>drugclass</listType>
			<listItem>
				<name>Stelara subcutaneous</name>
				<codeValue>02.153035</codeValue>
			</listItem>
		</listDef>
	</lists>
</paload>
